Resveratrol: an effective pharmacological agent to prevent inflammation-induced atrial fibrillation?

Naunyn Schmiedebergs Arch Pharmacol. 2018 Nov;391(11):1163-1167. doi: 10.1007/s00210-018-1566-5. Epub 2018 Sep 20.

Authors

Henry Sutanto¹, Dobromir Dobrev², Jordi Heijman³

Affiliations

¹ Department of Cardiology, CARIM School for cardiovascular diseases, Maastricht University, PO Box 616, 6200 MD, Maastricht, The Netherlands.
² Institute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Essen, Germany.
³ Department of Cardiology, CARIM School for cardiovascular diseases, Maastricht University, PO Box 616, 6200 MD, Maastricht, The Netherlands. jordi.heijman@maastrichtuniversity.nl.

PMID: 30238135
DOI: 10.1007/s00210-018-1566-5

No abstract available

Publication types

Editorial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Anti-Arrhythmia Agents
Atrial Fibrillation*
Humans
Inflammation
Resveratrol

Substances

Anti-Arrhythmia Agents
Resveratrol

Grants and funding